Maxim Group analyst Naz Rahman maintained a Buy rating on Neurosense Therapeutics Ltd. (NRSN – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.74.
Rahman covers the Healthcare sector, focusing on stocks such as Clene, scPharmaceuticals, and Neurosense Therapeutics Ltd.. According to TipRanks, Rahman has an average return of -15.5% and a 32.41% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurosense Therapeutics Ltd. with a $7.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $5.20 and a one-year low of $1.08. Currently, Neurosense Therapeutics Ltd. has an average volume of 1.47M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Read More on NRSN:
- NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
- NeuroSense, QuantalX partner in early detection of neurodegenerative diseases
- NeuroSense receives approval in Germany to enroll patients in Paradigm study
- NeuroSense announces Canada approved patient enrollment for PARADIGM study
